Recent Updates
Recently added Catalysts
QURE Negative Sentiment Score: 20/100

UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of Upcoming Deadline

Key Takeaway: Bernstein Liebhard LLP has issued a reminder to investors of uniQure N.V. regarding a class action lawsuit tied to alleged securities fraud. The lawsuit claims that the company misrepresented its drug AMT-130 intended for Huntington's Disease. Shareholders who purchased shares between September 24, 2025, and October 31, 2025, are advised to be aware of their legal options. The deadline for filing to be a lead plaintiff is April 13, 2026.

Market Sentiment Analysis

CONCERNS & RISKS

  • A securities fraud class action lawsuit has been initiated against uniQure.
  • The lawsuit alleges misrepresentations about AMT-130, a drug for Huntington's Disease.
  • Investors who owned shares between specific dates are potentially impacted.
  • There is an impending deadline for investors to join the lawsuit.

Full Press Release Details

NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Should You Join The uniQure Class Action Lawsuit:
Do you, or did you, own shares of uniQure N.V. (QURE)?
Did you purchase your shares between September 24, 2025 and October 31, 2025, inclusive?
Did you lose money in your investment in uniQure N.V.?
If you purchased or acquired uniQure ordinary shares, and/or would like to discuss your legal rights and options please visit uniQure N.V. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
If you wish to serve as lead plaintiff for the Class, you must file papers by April 13, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
A lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors (the “Class”) who purchased or acquired the ordinary shares of uniQure between September 24, 2025 and October 31, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.
According to the lawsuit, Defendants made misrepresentations concerning AMT-130, a drug the Company was developing for treatment of Huntington’s Disease.
About Bernstein Liebhard:
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2026 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

uniqure class action

Frequently Asked Questions

What is the deadline to join the uniQure class action lawsuit?

The deadline to file as a lead plaintiff is April 13, 2026.

Who can join the uniQure class action lawsuit?

Investors who owned uniQure shares from September 24 to October 31, 2025, can join.

What claims are made in the uniQure lawsuit?

The lawsuit alleges that uniQure made misrepresentations about AMT-130.

What costs are associated with joining the class action?

All representation is on a contingency fee basis; no fees are required upfront.

Who should I contact for more information about the lawsuit?

Contact Investor Relations Manager Peter Allocco at pallocco@bernlieb.com.

Last updated: Mar 26, 2026